-transparent.png){kind=logo}
To determine the role of telomere-mediated gene stability in hepatocarcinogenesis, we examined the telomere length of human liver with or without chronic liver diseases and hepatocellular carcinomas (HCC). The mean telomere restriction fragment (TRF) length of normal liver (n = 13), chronic hepatitis (n = 11), liver cirrhosis (n = 24) and HCC (n = 24) was 7.8 +/- 0.2, 7.1 +/- 0.3, 6.4 +/- 0.2 and 5.2 +/- 0.2 kb, respectively (mean +/- standard error). TRF length decreased with a progression of chronic liver diseases and that in HCC was significantly shorter than that in other chronic liver diseases (p < 0.05). The ratios of TRF length of HCC to that of corresponding surrounding liver of well differentiated (n = 7), moderately differentiated (n = 10) and poorly differentiated (n = 4) HCCs were 0.83 +/- 0.06, 0.75 +/- 0.05 and 0.98 +/- 0.09, respectively. The ratio of poorly differentiated HCC was significantly higher than that of moderately differentiated HCC (p < 0.05). A comparison between the size and telomere length ratio of moderately differentiated HCCs revealed a decrease of the ratio with size until it reached 50 mm in diameter. In contrast, the ratio increased as the size enlarged over 50 mm. These findings suggest that the gene stability of the liver cells mediated by the telomere is reduced as chronic liver disease progresses and that telomerase is activated in poorly differentiated HCC and moderately differentiated HCC over 50 mm in diameter.
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
October 2015,
Chest,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
May 2014,
Reproductive biomedicine online,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
October 2015,
Kardiologiia,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
January 2002,
Methods in molecular medicine,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
June 1995,
Biochemical and biophysical research communications,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
May 1996,
Human molecular genetics,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
December 2020,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
January 2005,
Clinical cancer research : an official journal of the American Association for Cancer Research,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
July 2013,
The FEBS journal,
Y Urabe, and
K Nouso, and
T Higashi, and
H Nakatsukasa, and
N Hino, and
K Ashida, and
N Kinugasa, and
K Yoshida, and
S Uematsu, and
T Tsuji
January 2014,
Current aging science,
